抗金黄色葡萄球菌抗体药物研究进展

Development of antibody drugs against Staphylococcus aureus

耐甲氧西林金黄色葡萄球菌(methicillin-resistant Staphylococcus aureus,MRSA)作为超级细菌的典型代表,严重威胁人类的健康。目前传统的抗生素治疗和疫苗主动预防都无法有效控制MRSA感染。金黄色葡萄球菌的毒力是由大量的毒力因子决定的,如黏附素、溶血素、自溶素、蛋白酶等。这些毒力因子能够协助菌体黏附、侵袭宿主,是引发机体组织损伤和脓毒症的主要原因。抗菌药物虽然具有较强的杀菌效果,但对毒力因子的作用欠佳,而且在抗菌药物反复作用下,MRSA会裂解释放更多毒素,加重感染。针对毒力因子的中和方面,以抗体为基础的治疗方法未来有望成为一种非常重要的治疗方法。本文主要对近年来国内外抗金黄色葡萄球菌抗体药物研究状况进行综述和展望。

Methicillin-resistant Staphylococcus aureus(MRSA),as a typical representative of super bacteria,have posed a serious threat to human health.At present,traditional antibiotic treatment and vaccine active prevention are unable to effectively control MRSA infection.The virulence of Staphylococcus aureus is determined by a large number of virulence factors,such as adhesive,hemolysin,autolysin,and protease.These virulence factors,assisting bacteria adhesion and invasion to the host,is the major causes of tissue injury and sepsis.Although antibiotics have strong sterilization effect,the effect of virulence factors is poor.When antibiotics are repeatedly applied,MRSA cleaves and releases more toxins,exacerbating the infection.In view of the virulence factors and aspects,therapy based on antibody will be a very important treatment.In this paper,the research status of antibody drugs against Staphylococcus aureus at home and abroad in recent years is reviewed and prospected.